Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

(2022) Adriaan A. Voors et al.   NATURE MEDICINE

Comments on “Sample size formula for a win ratio endpoint” by R. X. Yu and J. Ganju

(2022) Samvel B. Gasparyan et al.   STATISTICS IN MEDICINE

Win odds: An adaptation of the win ratio to include ties

(2021) Edgar Brunner et al.   STATISTICS IN MEDICINE

Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials

(2021) Samvel B. Gasparyan et al.   Journal of Biopharmaceutical Statistics

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Mikhail N Kosiborod et al.   Lancet Diabetes & Endocrinology

Endpoints for randomized controlled clinical trials for COVID-19 treatments

(2020) Lori E Dodd et al.   Clinical Trials

Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial

(2020) Scott R Evans et al.   Clinical Trials

Adjusted win ratio with stratification: Calculation methods and interpretation

(2020) Samvel B Gasparyan et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Lack of harmonization of coronavirus disease ordinal scales

(2020) Deborah A Zarin et al.   Clinical Trials

Effects of da pagliflozin on prevention of major clinical events and recovery in patients with re spiratory failure because of COVID‐ 19 : Design and rationale for the DARE‐19 study

(2020) Mikhail Kosiborod et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

A weighted combined effect measure for the analysis of a composite time-to-first-event endpoint with components of different clinical relevance

(2017) Geraldine Rauch et al.   STATISTICS IN MEDICINE

Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure

(2016) Milton Packer   CIRCULATION

Large sample inference for a win ratio analysis of a composite outcome based on prioritized components: Table 1.

(2015) Ionut Bebu et al.   BIOSTATISTICS

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

(2011) S. J. Pocock et al.   EUROPEAN HEART JOURNAL

Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

(2010) Marc Buyse   STATISTICS IN MEDICINE